Role of IV ketamine in suicidal risk reduction in patients with suicidality

Role of IV ketamine in suicidal risk reduction in patients with suicidality attending psychiatry department in a tertiary care hospital, a placebo based, double blinded, randomized controlled trial. - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/04/085835

Enrollment

Registered

2025-04-28

Start date

Unknown

Completion date

Unknown

Last updated

2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F322- Major depressive disorder, singleepisode, severe without psychotic features

Interventions

Intervention1: IV Ketamin: IV Ketamin(0.5mg/kg) in 100ml NS infused over 40minutes . 3 infusions given at 2 days interval. total 3 doses of ketamine are going to give. Control Intervention1: standard

Eligibility

Inclusion criteria

Inclusion criteria: having suicidal ideation measured in BSS Scale

Exclusion criteria

Exclusion criteria: cardiovascular disease intracranial hypertension head injury pregnancy breast feeding allergy to ketamin delrium substance use disorder except nicotine major psychotic disorder

Design outcomes

Primary

Measure	Time frame
remission of suicidal ideation measured in BSS scaleTimepoint: baseline 1 week 2 week 4 week 6 months	—

Countries

India

Contacts

Public ContactRajashree Mohanta

SCB Medical college and Hospital

drspswain@gmail.com9861014757

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026